Acute myeloid leukemia (AML) and other solid tumors have high mortality rates, partly due to the lack of highly selective therapies that can target cancer cells while sparing healthy tissue. Current treatments often result in significant alloimmune toxicity, limiting their effectiveness, especially in high-risk AML patients.

Yellowstone Biosciences is developing a therapeutic platform of T-cell bispecific therapies that target frequently expressed peptide antigens presented by HLA Class II on cancer cells. The company leverages a proprietary biobank of over 10,000 samples from AML patients, including a unique cohort of patients cured by allogeneic stem cell transplantation without alloimmune toxicity, to identify these antigens. By targeting these peptide-HLA complexes with bispecific molecules, Yellowstone aims to selectively kill tumor cells while minimizing harm to healthy cells. The initial focus is on AML, with plans to expand to other solid tumors exhibiting HLA Class II expression.

Proprietary biobank of over 10,000 AML patient samples to identify frequently expressed peptide antigens.

Focus on peptide antigens presented by HLA Class II, offering a novel target for cancer therapy.

Development of T-cell bispecific molecules designed to selectively kill tumor cells.

Initial lead program targeting AML, with potential applications in ovarian, non-small cell lung, colorectal, prostate, breast, renal cancers, and melanoma.

Utilizes insights from a rare cohort of high-risk AML patients cured by allogeneic stem cell transplantation without significant alloimmune toxicity.

The primary target audience includes patients with acute myeloid leukemia and other solid tumors expressing HLA Class II, as well as clinicians and researchers focused on developing more effective and less toxic cancer therapies.